{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:51:56Z","timestamp":1794009116216,"version":"4.8.0"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.cytogfr.2025.01.002","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T19:19:17Z","timestamp":1737659957000},"page":"35-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Interleukin-17: A pleiotropic cytokine implicated in inflammatory, infectious, and malignant disorders"],"prefix":"10.1016","volume":"83","author":[{"given":"Anushka","family":"Saran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Nishizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Lippman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumei","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.cytogfr.2025.01.002_bib1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2567.2009.03240.x","article-title":"Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease","volume":"129","author":"Onishi","year":"2010","journal-title":"Immunology"},{"issue":"6","key":"10.1016\/j.cytogfr.2025.01.002_bib2","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/1074-7613(95)90070-5","article-title":"Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor","volume":"3","author":"Yao","year":"1995","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.01.002_bib3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","article-title":"IL-17 and IL-17-producing cells in protection versus pathology","volume":"23","author":"Mills","year":"2023","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.01.002_bib4","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","article-title":"The IL-17 family of cytokines in health and disease","volume":"50","author":"McGeachy","year":"2019","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.cytogfr.2025.01.002_bib5","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1084\/jem.183.6.2593","article-title":"T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines","volume":"183","author":"Fossiez","year":"1996","journal-title":"J. Exp. Med."},{"issue":"19","key":"10.1016\/j.cytogfr.2025.01.002_bib6","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.1093\/emboj\/20.19.5332","article-title":"IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding","volume":"20","author":"Hymowitz","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/j.cytogfr.2025.01.002_bib7","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/ncomms2880","article-title":"Crystal structures of interleukin 17A and its complex with IL-17 receptor A","volume":"4","author":"Liu","year":"2013","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.01.002_bib8","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0092-8674(93)90127-C","article-title":"A structural superfamily of growth factors containing a cystine knot motif","volume":"73","author":"McDonald","year":"1993","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.01.002_bib9","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/prd.12083","article-title":"Basic biology and role of interleukin-17 in immunity and inflammation","volume":"69","author":"Zenobia","year":"2015","journal-title":"Periodontology 2000"},{"issue":"8","key":"10.1016\/j.cytogfr.2025.01.002_bib10","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nri2586","article-title":"Structure and signalling in the IL-17 receptor family","volume":"9","author":"Gaffen","year":"2009","journal-title":"Nat. Rev. Immunol."},{"issue":"18","key":"10.1016\/j.cytogfr.2025.01.002_bib11","doi-asserted-by":"crossref","first-page":"13447","DOI":"10.1074\/jbc.M700499200","article-title":"Identification of an interleukin 17F\/17A heterodimer in activated human CD4+ T cells","volume":"282","author":"Wright","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.01.002_bib12","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/cr.2007.35","article-title":"A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses","volume":"17","author":"Chang","year":"2007","journal-title":"Cell Res."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.01.002_bib13","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0968-0004(03)00067-7","article-title":"The STIR-domain superfamily in signal transduction, development and immunity","volume":"28","author":"Novatchkova","year":"2003","journal-title":"Trends Biochem. Sci."},{"issue":"43","key":"10.1016\/j.cytogfr.2025.01.002_bib14","doi-asserted-by":"crossref","first-page":"32751","DOI":"10.1074\/jbc.M110.121418","article-title":"SEF\/IL-17R (SEFIR) is not enough: an extended SEFIR domain is required for il-17RA-mediated signal transduction","volume":"285","author":"Onishi","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.cytogfr.2025.01.002_bib15","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/ni.1813","article-title":"Structural basis of receptor sharing by interleukin 17 cytokines","volume":"10","author":"Ely","year":"2009","journal-title":"Nat. Immunol."},{"issue":"197","key":"10.1016\/j.cytogfr.2025.01.002_bib16","doi-asserted-by":"crossref","first-page":"ra72","DOI":"10.1126\/scisignal.2001843","article-title":"A CC' loop decoy peptide blocks the interaction between Act1 and IL-17RA to attenuate IL-17- and IL-25-induced inflammation","volume":"4","author":"Liu","year":"2011","journal-title":"Sci. Signal."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.01.002_bib17","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/ni1439","article-title":"The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease","volume":"8","author":"Qian","year":"2007","journal-title":"Nat. Immunol."},{"issue":"15","key":"10.1016\/j.cytogfr.2025.01.002_bib18","doi-asserted-by":"crossref","first-page":"12881","DOI":"10.1074\/jbc.M110.199547","article-title":"IL-17-induced NF-kappaB activation via CIKS\/Act1: physiologic significance and signaling mechanisms","volume":"286","author":"S\u00f8nder","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"92","key":"10.1016\/j.cytogfr.2025.01.002_bib19","doi-asserted-by":"crossref","first-page":"ra63","DOI":"10.1126\/scisignal.2000382","article-title":"Act1, a U-box E3 ubiquitin ligase for IL-17 signaling","volume":"2","author":"Liu","year":"2009","journal-title":"Sci. Signal."},{"issue":"7","key":"10.1016\/j.cytogfr.2025.01.002_bib20","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1084\/jem.191.7.1233","article-title":"Requirement of tumor necrosis factor receptor-associated factor (TRAF)6 in interleukin 17 signal transduction","volume":"191","author":"Schwandner","year":"2000","journal-title":"J. Exp. Med."},{"issue":"47","key":"10.1016\/j.cytogfr.2025.01.002_bib21","doi-asserted-by":"crossref","first-page":"35603","DOI":"10.1074\/jbc.C600256200","article-title":"Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor","volume":"281","author":"Chang","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"19","key":"10.1016\/j.cytogfr.2025.01.002_bib22","doi-asserted-by":"crossref","first-page":"14088","DOI":"10.1074\/jbc.M109.017129","article-title":"Induction of neutrophil gelatinase-associated lipocalin expression by co-stimulation with interleukin-17 and tumor necrosis factor-alpha is controlled by IkappaB-zeta but neither by C\/EBP-beta nor C\/EBP-delta","volume":"285","author":"Karlsen","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.01.002_bib23","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1074\/jbc.M308809200","article-title":"Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT\/enhancer-binding protein family members","volume":"279","author":"Ruddy","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.01.002_bib24","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/eji.201747017","article-title":"Bcl-3 induced by IL-22 via STAT3 activation acts as a potentiator of psoriasis-related gene expression in epidermal keratinocytes","volume":"48","author":"Tohyama","year":"2018","journal-title":"Eur. J. Immunol."},{"issue":"18","key":"10.1016\/j.cytogfr.2025.01.002_bib25","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.1073\/pnas.0611589104","article-title":"Distinct functional motifs within the IL-17 receptor regulate signal transduction and target gene expression","volume":"104","author":"Maitra","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9","key":"10.1016\/j.cytogfr.2025.01.002_bib26","doi-asserted-by":"crossref","first-page":"5969","DOI":"10.1074\/jbc.C600322200","article-title":"Chromatin remodeling of interleukin-17 (IL-17)-IL-17F cytokine gene locus during inflammatory helper T cell differentiation","volume":"282","author":"Akimzhanov","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.01.002_bib27","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus Secukinumab in Plaque Psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.01.002_bib28","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.immuni.2008.11.009","article-title":"Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses","volume":"30","author":"Ishigame","year":"2009","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.cytogfr.2025.01.002_bib29","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/ni.3742","article-title":"Interleukin 17 is a chief orchestrator of immunity","volume":"18","author":"Veldhoen","year":"2017","journal-title":"Nat. Immunol."},{"issue":"6025","key":"10.1016\/j.cytogfr.2025.01.002_bib30","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1126\/science.1200439","article-title":"Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity","volume":"332","author":"Puel","year":"2011","journal-title":"Sciences"},{"issue":"2","key":"10.1016\/j.cytogfr.2025.01.002_bib31","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cyto.2013.07.022","article-title":"IL-17 family: cytokines, receptors and signaling","volume":"64","author":"Gu","year":"2013","journal-title":"Cytokine"},{"issue":"9","key":"10.1016\/j.cytogfr.2025.01.002_bib32","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.01.002_bib33","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40265-015-0359-0","article-title":"Secukinumab: first global approval","volume":"75","author":"Sanford","year":"2015","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.cytogfr.2025.01.002_bib34","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","article-title":"Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study","volume":"76","author":"Braun","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"26","key":"10.1016\/j.cytogfr.2025.01.002_bib35","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an Interleukin-17A Inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.01.002_bib36","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/annrheumdis-2019-216118","article-title":"Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)","volume":"79","author":"Dougados","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.01.002_bib37","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/ard-2022-222849","article-title":"Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial","volume":"82","author":"Brunner","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"10378","key":"10.1016\/j.cytogfr.2025.01.002_bib38","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.01.002_bib39","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/art.41477","article-title":"Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study","volume":"73","author":"Deodhar","year":"2021","journal-title":"Arthritis Rheumatol."},{"issue":"10217","key":"10.1016\/j.cytogfr.2025.01.002_bib40","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","article-title":"Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.cytogfr.2025.01.002_bib41","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis--results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.01.002_bib42","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/bjd.13348","article-title":"Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)","volume":"172","author":"Blauvelt","year":"2015","journal-title":"Br. J. Dermatol."},{"issue":"6","key":"10.1016\/j.cytogfr.2025.01.002_bib43","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/jdv.12751","article-title":"Efficacy, safety and usability of secukinumab administration by autoinjector\/pen in psoriasis: a randomized, controlled trial (JUNCTURE)","volume":"29","author":"Paul","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol.: JEADV"},{"issue":"4","key":"10.1016\/j.cytogfr.2025.01.002_bib44","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2025.01.002_bib45","doi-asserted-by":"crossref","unstructured":"Papp K., Leonardi C., Blauvelt A., et al. Efficacy of ixekizumab therapy: integrated analysis of 3 double-blind, controlled trials (UNCOVER-1, UNCOVER-2, UNCOVER-3) [abstract no. 3031 plus poster]. In: 74th Annual Meeting of the American Academy of Dermatology; 2016.","DOI":"10.1016\/j.jid.2016.06.075"},{"issue":"14","key":"10.1016\/j.cytogfr.2025.01.002_bib46","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.cytogfr.2025.01.002_bib47","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/bjd\/ljad035","article-title":"Bimekizumab maintenance of response through 3\u2005years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial","volume":"188","author":"Strober","year":"2023","journal-title":"Br. J. Dermatol."},{"issue":"14","key":"10.1016\/j.cytogfr.2025.01.002_bib48","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with Psoriatic Arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"9999","key":"10.1016\/j.cytogfr.2025.01.002_bib49","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.01.002_bib50","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"Mease","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.cytogfr.2025.01.002_bib51","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1007\/s10067-022-06218-8","article-title":"Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results","volume":"41","author":"Coates","year":"2022","journal-title":"Clin. Rheumatol."},{"issue":"9","key":"10.1016\/j.cytogfr.2025.01.002_bib52","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3390\/ijms17091433","article-title":"Targeting the tumor microenvironment: the protumor effects of IL-17 related to cancer type","volume":"17","author":"Fabre","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.01.002_bib53","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/01.NNR.0000280655.58266.6c","article-title":"Cytokine comparisons between women with breast cancer and women with a negative breast biopsy","volume":"57","author":"Lyon","year":"2008","journal-title":"Nurs. Res."},{"issue":"6","key":"10.1016\/j.cytogfr.2025.01.002_bib54","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2195","article-title":"IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines","volume":"10","author":"Zhu","year":"2008","journal-title":"Breast Cancer Res.: BCR"},{"issue":"5","key":"10.1016\/j.cytogfr.2025.01.002_bib55","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1158\/2159-8290.CD-11-0100","article-title":"TGF-\u03b2 receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms","volume":"1","author":"Novitskiy","year":"2011","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.01.002_bib56","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3892\/mmr.2012.1036","article-title":"Interleukin-17, produced by lymphocytes, promotes tumor growth and angiogenesis in a mouse model of breast cancer","volume":"6","author":"Du","year":"2012","journal-title":"Mol. Med. Rep."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.01.002_bib57","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/carcin\/bgs342","article-title":"Interleukin-17 induces AP-1 activity and cellular transformation via upregulation of tumor progression locus 2 activity","volume":"34","author":"Kim","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.cytogfr.2025.01.002_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/srep11874","article-title":"IL-17A and its homologs IL-25\/IL-17E recruit the c-RAF\/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells","volume":"5","author":"Mombelli","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cytogfr.2025.01.002_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.582863","article-title":"Estrogen Receptor Downregulates Expression of PD-1\/PD-L1 and Infiltration of CD8+ T Cells by Inhibiting IL-17 Signaling Transduction in Breast Cancer","volume":"10","author":"Shuai","year":"2020","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.cytogfr.2025.01.002_bib60","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.3109\/00365521.2012.725089","article-title":"IL-17A in the tumor microenvironment of the human colorectal adenoma-carcinoma sequence","volume":"47","author":"Cui","year":"2012","journal-title":"Scand. J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.01.002_bib61","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/s41385-019-0176-y","article-title":"The IL-33\/ST2 pathway shapes the regulatory T cell phenotype to promote intestinal cancer","volume":"12","author":"Pastille","year":"2019","journal-title":"Mucosal Immunol."},{"issue":"8","key":"10.1016\/j.cytogfr.2025.01.002_bib62","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/0008-5472.CAN-15-0749","article-title":"redundant innate and adaptive sources of IL17 production drive colon tumorigenesis","volume":"76","author":"Housseau","year":"2016","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.cytogfr.2025.01.002_bib63","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2009-03-208249","article-title":"Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments","volume":"114","author":"Kryczek","year":"2009","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.cytogfr.2025.01.002_bib64","first-page":"3698","article-title":"Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice","volume":"59","author":"Tartour","year":"1999","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.01.002_bib65","doi-asserted-by":"crossref","DOI":"10.4161\/2162402X.2014.984539","article-title":"Angels and demons: Th17 cells represent a beneficial response, while neutrophil IL-17 is associated with poor prognosis in squamous cervical cancer","volume":"4","author":"Punt","year":"2015","journal-title":"Oncoimmunology"},{"issue":"5","key":"10.1016\/j.cytogfr.2025.01.002_bib66","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/onc.2016.240","article-title":"Interleukin-17 promotes prostate cancer via MMP7-induced epithelial-to-mesenchymal transition","volume":"36","author":"Zhang","year":"2017","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.cytogfr.2025.01.002_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032126","article-title":"IL-17 mediated inflammation promotes tumor growth and progression in the skin","volume":"7","author":"He","year":"2012","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.cytogfr.2025.01.002_bib68","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1084\/jem.20090207","article-title":"IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway","volume":"206","author":"Wang","year":"2009","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.01.002_bib69","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/s41385-019-0176-y","article-title":"The IL-33\/ST2 pathway shapes the regulatory T cell phenotype to promote intestinal cancer","volume":"12","author":"Pastille","year":"2019","journal-title":"Mucosal Immunol."},{"issue":"9","key":"10.1016\/j.cytogfr.2025.01.002_bib70","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/nm.3333","article-title":"IL-17 mediates resistance to anti-VEGF therapy","volume":"19","author":"Maniati","year":"2013","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.01.002_bib71","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jdermsci.2015.06.011","article-title":"Association between single nucleotide polymorphisms IL17RA rs4819554 and IL17E rs79877597 and Psoriasis in a Spanish cohort","volume":"80","author":"Batalla","year":"2015","journal-title":"J. Dermatol. Sci."},{"issue":"7","key":"10.1016\/j.cytogfr.2025.01.002_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158905","article-title":"A single nucleotide polymorphism in the Il17ra promoter is associated with functional severity of ankylosing spondylitis","volume":"11","author":"Vidal-Casti\u00f1eira","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.cytogfr.2025.01.002_bib73","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/sj.jid.5701213","article-title":"Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells","volume":"128","author":"Lowes","year":"2008","journal-title":"J. Invest. Dermatol."},{"issue":"10","key":"10.1016\/j.cytogfr.2025.01.002_bib74","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/ni.3523","article-title":"CD1a on Langerhans cells controls inflammatory skin disease","volume":"17","author":"Kim","year":"2016","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.01.002_bib75","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/art.41156","article-title":"Polyfunctional, proinflammatory, Tissue-Resident memory phenotype and function of synovial Interleukin-17A+ CD 8+ T cells in psoriatic arthritis","volume":"72","author":"Steel","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.cytogfr.2025.01.002_bib76","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nature05505","article-title":"Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis","volume":"445","author":"Zheng","year":"2007","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.cytogfr.2025.01.002_bib77","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/1529-0131(199905)42:5<963::AID-ANR15>3.0.CO;2-E","article-title":"Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium","volume":"42","author":"Chabaud","year":"1999","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.cytogfr.2025.01.002_bib78","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.4049\/jimmunol.164.5.2832","article-title":"High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism","volume":"164","author":"Ziolkowska","year":"2000","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.cytogfr.2025.01.002_bib79","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.4049\/jimmunol.160.7.3513","article-title":"IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages","volume":"160","author":"Jovanovic","year":"1998","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.01.002_bib80","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cyto.2007.09.014","article-title":"IL-17\/Th17 targeting: on the road to prevent chronic destructive arthritis?","volume":"41","author":"Lubberts","year":"2008","journal-title":"Cytokine"},{"issue":"7","key":"10.1016\/j.cytogfr.2025.01.002_bib81","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1006\/cyto.2000.0681","article-title":"Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis","volume":"12","author":"Chabaud","year":"2000","journal-title":"Cytokine"},{"issue":"11","key":"10.1016\/j.cytogfr.2025.01.002_bib82","doi-asserted-by":"crossref","first-page":"6173","DOI":"10.4049\/jimmunol.171.11.6173","article-title":"Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice","volume":"171","author":"Nakae","year":"2003","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.01.002_bib83","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/art.20001","article-title":"Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion","volume":"50","author":"Lubberts","year":"2004","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.cytogfr.2025.01.002_bib84","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/jid.2012.194","article-title":"The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings","volume":"133","author":"Martin","year":"2013","journal-title":"J. Invest. Dermatol."},{"issue":"7128","key":"10.1016\/j.cytogfr.2025.01.002_bib85","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nature05505","article-title":"Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis","volume":"445","author":"Zheng","year":"2007","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.cytogfr.2025.01.002_bib86","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1038\/jid.2013.237","article-title":"IL-17 and TNF synergistically modulate cytokine expression while suppressing melanogenesis: potential relevance to psoriasis","volume":"133","author":"Wang","year":"2013","journal-title":"J. Invest. Dermatol."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.01.002_bib87","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"issue":"13","key":"10.1016\/j.cytogfr.2025.01.002_bib88","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1084\/jem.20071094","article-title":"Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses","volume":"204","author":"Zaba","year":"2007","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.01.002_bib89","doi-asserted-by":"crossref","first-page":"R569","DOI":"10.1186\/ar1698","article-title":"Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis","volume":"7","author":"Kruithof","year":"2005","journal-title":"Arthritis Res. Ther."},{"issue":"2","key":"10.1016\/j.cytogfr.2025.01.002_bib90","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s12016-012-8307-1","article-title":"Role of IL-17 in psoriasis and psoriatic arthritis","volume":"44","author":"Raychaudhuri","year":"2013","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"3","key":"10.1016\/j.cytogfr.2025.01.002_bib91","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/art.41156","article-title":"Polyfunctional, proinflammatory, tissue-resident memory phenotype and function of synovial interleukin-17A+CD8+ T Cells in Psoriatic Arthritis","volume":"72","author":"Steel","year":"2020","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"10.1016\/j.cytogfr.2025.01.002_bib92","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s13555-021-00554-4","article-title":"Efficacy and safety of netakimab, A novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. results of A 54-week randomized double-blind placebo-controlled PLANETA clinical trial","volume":"11","author":"Puig","year":"2021","journal-title":"Dermatol. Ther."},{"issue":"10284","key":"10.1016\/j.cytogfr.2025.01.002_bib93","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","article-title":"IL17A\/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study","volume":"397","author":"Papp","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cytogfr.2025.01.002_bib94","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2209920","article-title":"Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis","volume":"15","author":"Klint","year":"2023","journal-title":"mAbs"},{"issue":"10","key":"10.1016\/j.cytogfr.2025.01.002_bib95","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/exd.14619","article-title":"IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: combined results from a pre-clinical and phase II proof-of-concept study","volume":"31","author":"Kimball","year":"2022","journal-title":"Exp. Dermatol."},{"issue":"10","key":"10.1016\/j.cytogfr.2025.01.002_bib96","first-page":"2249","article-title":"Dermatologic disease-directed targeted therapy (D3T2): the application of biomarker-based precision medicine for the personalized treatment of skin conditions-precision dermatology","volume":"12","author":"Cohen","year":"2022","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.cytogfr.2025.01.002_bib97","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13073-022-01102-1","article-title":"Clinical trial design in the era of precision medicine","volume":"14","author":"Fountzilas","year":"2022","journal-title":"Genome Med"},{"issue":"11","key":"10.1016\/j.cytogfr.2025.01.002_bib98","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jamaoncol.2016.2129","article-title":"Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis","volume":"2","author":"Schwaederle","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.cytogfr.2025.01.002_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102703","article-title":"Tumor-agnostic baskets to N-of-1 platform trials and real-world data: transforming precision oncology clinical trial design","volume":"125","author":"Fountzilas","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.cytogfr.2025.01.002_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102019","article-title":"Review of precision cancer medicine: evolution of the treatment paradigm","volume":"86","author":"Tsimberidou","year":"2020","journal-title":"Cancer Treat. Rev."}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610125000024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610125000024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T20:56:00Z","timestamp":1777323360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610125000024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":100,"alternative-id":["S1359610125000024"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2025.01.002","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-17: A pleiotropic cytokine implicated in inflammatory, infectious, and malignant disorders","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2025.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}